. 2014 Jul 3;100(21):1681–1687. doi: 10.1136/heartjnl-2014-305673

Table 3.

Scenario analysis results from the discrete-event simulation model

Scenario	Country	Incremental costs	Incremental QALYs	ICER
Using EMPHASIS-HF data with no extrapolation	UK	£940	0.05	£20 730
Using EMPHASIS-HF data with no extrapolation	Spain	€1427	0.05	€31 138
Time horizon 2 years	UK	£717	0.04	£20 101
Time horizon 2 years	Spain	€1157	0.04	€32 208
Time horizon 5 years	UK	£1160	0.19	£6016
Time horizon 5 years	Spain	€2340	0.20	€11 932
No utility decrement for adverse events, atrial fibrillation or hospitalisations	UK	£4284	1.20	£3558
	Spain	€7358	1.32	€5584
Increased use of devices	UK	£4495	1.22	£3693
Increased use of devices	Spain	€7396	1.33	€5560
No use of devices	UK	£3440	1.23	£2802
No use of devices	Spain	€5223	1.34	€3893

EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.